Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Diseases 1

Interventions

ibrutinib 2Rituximab 2venetoclax 1ponatinib 1fludarabine 1enzalutamide 1durvalumab 1dacetuzumab 1blinatumomab 1Lenalidomide 1Cyclophosphamide 1CA-4948 1Bendamustine Hydrochloride 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphatic Diseases × dacetuzumab × Clear all
NCT00283101 2014-12-18

A Safety Study in Patients With Chronic Lymphocytic Leukemia

Seagen Inc.

Phase 1/2 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡